- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05826847
Prone Positioning and Thoracoabdominal Binding on Lung and Muscle Protection in ARDS Patients During Spontaneous Breathing
Effect of Prone Positioning and Thoracoabdominal Binding on Lung and Muscle Protection in ARDS Patients With ICU-acquired Weakness Transitioning From Controlled to Spontaneous Breathing
Ventilator-induced diaphragmatic dysfunction and intensive care unit (ICU)-acquired weakness are two consequences of prolonged mechanical ventilation and critical illness in patients with acute respiratory distress syndrome (ARDS). Both complicate the process of withdrawing mechanical ventilation, increase hospital mortality and cause chronic disability in survivors. During transition from controlled to spontaneous breathing, these complications of critical illness favor an abnormal respiratory pattern and recruit accessory respiratory muscles which may promote additional lung and muscle injury. The type of ventilatory support and positioning may affect the muscle dysfunction and patient-self-inflicted lung injury at spontaneous breathing onset. In that regard, ARDS patients with ventilator-induced diaphragmatic dysfunction and ICU-acquired weakness who are transitioning from controlled to partial ventilatory support probably present an abnormal respiratory pattern which exacerbates lung and muscle injury. Physiological-oriented ventilatory approaches based on prone positioning or semi recumbent positioning with abdominal binding at spontaneous breathing onset, could decrease lung and muscle injury by favoring a better neuromuscular efficiency, and preventing intense inspiratory efforts and high transpulmonary driving pressures, as well as high-magnitude pendelluft. In the current project, in addition to perform a multimodal description of the severity of ventilator-induced diaphragmatic dysfunction and ICU-acquired weakness in prolonged mechanically ventilated ARDS patients, prone positioning and supine plus thoracoabdominal binding at spontaneous breathing onset will be evaluated.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The study was designed in three phases: a multimodal physiological description, a randomized crossover trial, and a pilot randomized trial. The multimodal physiological description and the randomized crossover trial were conducted in the same cohort. The pilot randomized trial was not conducted.
Multimodal Physiological Description Phase: a multimodal physiological description was performed to characterize ICU acquired weakness and ventilator-induced diaphragm dysfunction in prolonged mechanically ventilated ARDS patients at spontaneous breathing onset, in pressure support ventilation mode. The assessments included conventional electromyography (cEMG); electrical activity of the diaphragm; respiratory muscle ultrasound; respiratory flow; tidal volume; airway, esophageal and gastric pressures; and hemodynamic and electrical impedance tomography monitoring. Diaphragm ultrasound and cEMG were performed after the crossover trial, to avoid reducing PEEP and PS to the standardized low values required for diaphragm ultrasound (PEEP and PS of 6 cmH2O) before the crossover conditions, which could alter respiratory mechanics at protocol entry; cEMG findings were not expected to change over this timeframe (amendment approved by IRB No. 45/2024; May 15, 2024).
Randomized Crossover Trial Phase: Patients were asigened in random order to three 60-minute conditions on pressure support ventilation mode: A.- Control group: semi-recumbent position at 45º (previously described as supine at 45º), B.- Thoracoabdominal binding: semi-recumbent position at 45º plus thoracoabdominal binding, C.- Prone positioning (without thoracoabdominal binding). These strategies were performed under individualized PEEP (obtained at the lowest combination of collapse and overdistension according to electrical impedance tomography), with 15-minute washout periods of in assisted/controlled ventilation between conditions.
Pilot Randomized Trial Phase: This phase was designed to randomize patients to one of the three strategies under standard PEEP (ARDSNet strategy), with PET/CT imaging and biomarker analysis. The originally registered enrollment (n = 36) corresponded to this phase. A protocol amendment approved by the local ethics committee in May 2024 established that patients enrolled in this phase were not required to have completed the multimodal description and crossover phases, and reduced the planned sample size to 12 patients due to budgetary and logistical constraints. The phase was ultimately not conducted; the decision not to conduct it was reported to the local ethics committee and approved by the national funding agency.
Enrollment: The target enrollment for the crossover phase (24 patients) was established in the May 2024 protocol amendment. Recruitment was closed after 14 patients had been enrolled.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Independencia, Chile
- Hospital Clínico Universidad de Chile
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adult ARDS patients with moderate-severe ARDS on controlled protective mechanical ventilation for more than 2 days (modified from "more than 3 days" by the protocol amendment approved in May 2024)
- Stable hemodynamics
- Level of consciousness enough to initiate spontaneous breathing
Exclusion Criteria:
- Unstable hemodynamics
- Tracheostomy
- Abnormal level of consciousness
- Central nervous system injury
- Esophageal varices
- Pregnancy
- Contraindications for installation of electrical impedance tomography or nasogastric catheter placement
- Contraindications for prone positioning and thoracoabdominal binding
- Chronic neuromuscular disorders
- Obstructive lung disease; intrinsic positive end-expiratory pressure (PEEP) ≥3 cmH₂O (measured without inspiratory effort);
- Recent-onset sepsis and moderate-to-severe metabolic acidosis;
- Multi-organ failure with high short-term mortality risk
- Clinical evidence of respiratory or hemodynamic instability
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Control Group
ARDS patients at spontaneous breathing onset on pressure support ventilation mode in semi-recumbent position at 45º degrees, performed under individualized PEEP applied in random order. |
ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order. |
|
Experimental: Prone Positioning
ARDS patients at spontaneous breathing onset on pressure support ventilation mode in prone position, performed under individualized PEEP applied in random order. |
Prone positioning will be performed according to ICU local protocol with trained provider teams. |
|
Experimental: Thoracoabdominal Binding
ARDS patients at spontaneous breathing onset on pressure support ventilation mode in semi-recumbent position at 45º degrees using thoracoabdominal binding with the binder's upper edge above the costal margin, performed under individualized PEEP applied in random order. |
Thoracoabdominal binding will be used in semi-recumbent position (at 45º) and titrated to obtain a approximately 20% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
(Randomized Crossover Trial Phase) Pendelluft Magnitude
Prazo: One hour on each ventilatory strategy
|
Pendelluft magnitude monitored by electrical impedance tomography, analyzed as a continuous variable. Title corrected in September 2026 from "High-Magnitude Pendelluft", as no threshold was prespecified and the sample size calculation was based on a continuous outcome, according to the protocol amendment approved in May 2024. |
One hour on each ventilatory strategy
|
|
(Randomized Crossover Trial Phase) Neuromechanical Coupling of the Diaphragm
Prazo: One hour on each ventilatory strategy
|
Ratio between transdiaphragmatic pressure and electrical activity of the diaphragm, measured by an esophageal/gastric catheter. Co-primary outcome with pendelluft magnitude. Prespecified as primary in the ethics-approved protocol and described in the Brief Summary and as a secondary outcome of the Pilot Randomized Trial Phase, but omitted in error from the Crossover Phase outcomes in the original registration. Added in September 2026. |
One hour on each ventilatory strategy
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
(Randomized Crossover Trial Phase) Respiratory Mechanics Variables
Prazo: One hour on each ventilatory strategy
|
Esophageal pressure swing, gastric pressure, transdiaphragmatic pressure and transpulmonary driving pressure measured by a esophageal/gastric catheter |
One hour on each ventilatory strategy
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Rodrigo Cornejo, University of Chile
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1221829
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified individual participant data underlying the published results will be available upon reasonable request to the principal investigator, subject to approval by the local ethics committee and a data use agreement.
Prazo de Compartilhamento de IPD
Beginning after publication, for 5 years.
Critérios de acesso de compartilhamento IPD
Researchers with a methodologically sound proposal, after ethics committee approval.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .